4.4 Article

Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study

Journal

FUTURE ONCOLOGY
Volume 9, Issue 2, Pages 283-294

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/FON.12.183

Keywords

American Association for the Study of Liver Diseases guidelines; field practice; hepatocellular carcinoma; Italy; liver cancer; management

Categories

Ask authors/readers for more resources

Aim: Adherence to and the applicability of practice guidelines for the management of hepatocellular carcinoma (HCC) in field practice have not been fully addressed. We designed a multicenter field practice prospective study to evaluate the adherence to the 2005 American Association for the Study of Liver Diseases guidelines in Italy. Materials & methods: The study began in September 2008 and consecutively enrolled cirrhotic patients with newly diagnosed HCC from 30 local, nonreference centers in Italy. Patients were stratified according to Child-Pugh, the model for end-stage liver disease, tumor-node metastasis, performance status and the Barcelona Clinic Liver Cancer (BCLC) classifications. The diagnostic and therapeutic strategies adopted in each individual patient were recorded. Statistical analysis was carried out on 536 patients using all of the valuable data. Results: A total of 286 (54.5%) patients were >= 70 years old. Comorbidities, recorded in 397 (74%) patients, were classified as moderate to severe in 170 patients (43%). Overall, 174 (59%) patients with early-stage BCLC were >= 70 years; 104 (35%) of these had moderate-to-severe comorbidities and 54% were under a regular US surveillance program. Diagnosis was performed by computed tomography in 93% of patients, contrast-enhanced ultrasound in 62% and MRI in 17%. In patients with nodules of <= 2 cm, adherence to noninvasive diagnostic criteria was 56%. Adherence to the BCLC classification was shown to be suboptimal overall, particularly regarding allocation to surgical procedures, and a total of 119 patients (40%) with BCLC stage A did not receive curative therapies. Conclusions: This multicenter survey showed that, in the 'real world', adherence to the both the diagnostic and therapeutic American Association for the Study of Liver Diseases 2005 algorithms was low, particularly in patients with early-stage HCC. Difficulties in applying the algorithms in routine clinical practice and the high prevalence of older patients with relevant comorbidities may account for our findings. Strategies to help improve adherence to international guidelines for HCC in field practice are required.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database

Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio Dalla Riva, Edoardo G. Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati

Summary: This study compared patients with MAFLD and non-MAFLD who had hepatocellular carcinoma (HCC) in Italy. It found that the proportion of MAFLD in HCC patients was increasing over time and is expected to surpass non-MAFLD in the future. Despite a later cancer stage at diagnosis, MAFLD HCC patients had a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
Article Virology

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination

Luigia Trabace, Lorenzo Pace, Maria Grazia Morgese, Isabel Bianca Santo, Domenico Galante, Stefania Schiavone, Dora Cipolletta, Anna Maria Rosa, Pierluigi Reveglia, Antonio Parisi, Paolo Tucci, Giovanni Pepe, Rodolfo Sacco, Maria Pia Foschino Barbaro, Gaetano Corso, Antonio Fasanella

Summary: The Delta variant has raised concerns about its ability to evade SARS-CoV-2 vaccines. This study evaluated the neutralizing response of 172 Italian healthcare workers three months after receiving the Comirnaty vaccine. The results showed that the vaccine provides sustained neutralizing antibody activity against the Alpha variant, but it is less effective against the Gamma and even less against the Delta variants.

VIRUSES-BASEL (2022)

Article Gastroenterology & Hepatology

Real-time determination of gastric juice pH with EndoFaster® for atrophic gastritis assessment

Angelo Zullo, Bastianello Germana, Ermenegildo Galliani, Andrea Iori, Giovanni de Pretis, Guido Manfredi, Elisabetta Buscarini, Mario Ciuffi, Orazio Ignomirelli, Fabio Farinati, Edoardo Savarino, Paolo Pallini, Luisa Milan, Rita Conigliaro, Giuseppe Grande, Renato Cannizzaro, Stefania Maiero, Antonio Pisani, Stefania Marangi, Raffaele Manta, Olivia Morelli, Sergio Peralta, Alessia La Mantia, Matteo Rossano Buonocore, Kareem Khalal, Cesare Hassan, Fabio Monica

Summary: This study evaluated the accuracy of EndoFaster(R) device in ruling out gastric mucosal atrophy and found that it had a high negative predictive value in excluding atrophic gastritis, reducing the need for gastric biopsies.

DIGESTIVE AND LIVER DISEASE (2022)

Article Clinical Neurology

Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion

Federica Garri, Francesco Paolo Russo, Tommaso Carrer, Luca Weis, Francesca Pistonesi, Michele Mainardi, Michele Sandre, Edoardo Savarino, Fabio Farinati, Francesca Del Sorbo, Paola Soliveri, Daniela Calandrella, Roberta Biundo, Miryam Carecchio, Anna Lena Zecchinelli, Gianni Pezzoli, Angelo Antonini

Summary: This study retrospectively analyzed the usage of LCIG in 79 patients with Parkinson's disease and found that it has a relatively satisfactory long-term safety profile and efficacy, with a low rate of discontinuation. Peristomal complications may be a predictor of longer duration of therapy.

JOURNAL OF NEUROLOGY (2022)

Review Medicine, General & Internal

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Maria Guarino, Valentina Cossiga, Mario Capasso, Chiara Mazzarelli, Filippo Pelizzaro, Rodolfo Sacco, Francesco Paolo Russo, Alessandro Vitale, Franco Trevisani, Giuseppe Cabibbo

Summary: The COVID-19 outbreak has significantly impacted healthcare systems worldwide, particularly for patients with hepatocellular carcinoma (HCC). Reshaping clinical practice is necessary to ensure patient care and safety. Due to the pandemic measures, HCC surveillance has decreased and care for HCC patients has been rearranged.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Oncology

Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review

Daryl Ramai, Smit S. Deliwala, Saurabh Chandan, Janice Lester, Jameel Singh, Jayanta Samanta, Sara di Nunzio, Fabio Perversi, Francesca Cappellini, Aashni Shah, Michele Ghidini, Rodolfo Sacco, Antonio Facciorusso, Luca Giacomelli

Summary: Porphyria is a metabolic condition that can lead to liver cancer. Our study found that patients with porphyria are at an increased risk of developing primary liver malignancy. Therefore, routine surveillance should be conducted to detect liver cancer early in these patients.

CANCERS (2022)

Article Gastroenterology & Hepatology

Real-time gastric juice analysis with EndoFaster for H. pylori diagnosis: a large, multicentre study

Angelo Zullo, Bastianello Germana, Ermenegildo Galliani, Andrea Iori, Giovanni de Pretis, Guido Manfredi, Elisabetta Buscarini, Mario Ciuffi, Orazio Ignomirelli, Fabio Farinati, Edoardo Savarino, Paolo Pallini, Luisa Milan, Rita Conigliaro, Giuseppe Grande, Renato Cannizzaro, Stefania Maiero, Antonio Pisani, Stefania Marangi, Raffaele Manta, Olivia Morelli, Sergio Peralta, La Mantia Alessia, Matteo Rossano Buonocore, Fabio Monica

Summary: This study aimed to assess the accuracy of different versions of the EndoFaster device operating with different amounts of gastric juice. The results showed that the device version operating with 3 ml of gastric juice had a high accuracy in excluding H. pylori infection, and was not affected by medication or previous treatment.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Surgery

Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery

Simone Famularo, Matteo Donadon, Federica Cipriani, Federico Fazio, Francesco Ardito, Maurizio Iaria, Pasquale Perri, Simone Conci, Tommaso Dominioni, Quirino Lai, Giuliano La Barba, Stefan Patauner, Sarah Molfino, Paola Germani, Giuseppe Zimmitti, Enrico Pinotti, Matteo Zanello, Luca Fumagalli, Cecilia Ferrari, Maurizio Romano, Antonella Delvecchio, Maria Grazia Valsecchi, Adelmo Antonucci, Fabio Piscaglia, Fabio Farinati, Yoshikuni Kawaguchi, Kiyoshi Hasegawa, Riccardo Memeo, Giacomo Zanus, Guido Griseri, Marco Chiarelli, Elio Jovine, Mauro Zago, Moh'd Abu Hilal, Paola Tarchi, Gian Luca Baiocchi, Antonio Frena, Giorgio Ercolani, Massimo Rossi, Marcello Maestri, Andrea Ruzzenente, Gian Luca Grazi, Raffaele Dalla Valle, Fabrizio Romano, Felice Giuliante, Alessandro Ferrero, Luca Aldrighetti, Davide P. Bernasconi, Guido Torzilli

Summary: This study aimed to create a machine learning predictive model to allocate patients with recurrent hepatocellular carcinoma (HCC) to their best potential treatment based on their specific characteristics. An individualized algorithm for treatment allocation was developed using factors such as age, cirrhosis, number and size of recurrent nodules, extrahepatic spread, and time to recurrence. The algorithm provides recommendations for the best potential treatment according to patients' profiles.

JAMA SURGERY (2023)

Article Clinical Neurology

Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease

Aron Emmi, Michele Sandre, Francesco Paolo Russo, Giulia Tombesi, Federica Garri, Marta Campagnolo, Miryam Carecchio, Roberta Biundo, Gaya Spolverato, Veronica Macchi, Edoardo Savarino, Fabio Farinati, Piero Parchi, Andrea Porzionato, Luigi Bubacco, Raffaele De Caro, Gabor G. Kovacs, Angelo Antonini

Summary: This study revealed the presence of neuronal dysfunction and reactive gliosis in the duodenum of patients with Parkinson's disease, suggesting that the enteric nervous system is involved in the pathophysiology of the disease.

MOVEMENT DISORDERS (2023)

Article Oncology

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma

Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito

Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.

CANCERS (2023)

Review Biochemistry & Molecular Biology

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance

Filippo Pelizzaro, Fabio Farinati, Franco Trevisani

Summary: In recent years, immune checkpoint inhibitors (ICIs) have significantly improved the treatment of hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab has become the standard frontline treatment for advanced stage HCC. However, not all patients benefit from immunotherapy, and identifying predictive biomarkers for response or resistance is crucial for optimal treatment selection. This review aims to summarize available data on tumor and clinical features associated with response or resistance to immunotherapies in HCC.

BIOMEDICINES (2023)

Article Endocrinology & Metabolism

Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia

S. Censi, S. Carducci, G. Zoppini, A. Toffalini, V. Tonelli, J. Manso, C. Sabbadin, F. Galuppini, G. Pennelli, I. Piva, S. Barollo, L. Bertazza, V. Pilotto, D. Basso, B. Fabris, S. Bernardi, F. Farinati, C. Scaroni, C. Mian

Summary: This study investigated whether autoimmune atrophic gastritis (AAG) and chronic hypergastrinemia are associated with increased calcitonin (Ct) levels. The results showed that high gastrin levels in patients with AAG do not explain hypercalcitonemia, regardless of the presence of autoimmune thyroiditis (AT). Therefore, further diagnostic evaluation is necessary to rule out medullary thyroid cancer (MTC) in patients with high Ct levels and AAG.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2023)

Review Medicine, General & Internal

Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies

Elisa Pinto, Filippo Pelizzaro, Fabio Farinati, Francesco Paolo Russo

Summary: Hepatocellular carcinoma (HCC) is a common liver malignancy, and angiogenesis plays a crucial role in its development and progression. Deregulated angiogenic pathways have been identified as therapeutic targets in HCC. Locoregional and systemic treatments aim to disrupt tumor blood supply, but this may induce neoangiogenesis and tumor recurrence. Currently available tyrosine kinase inhibitors and monoclonal antibodies primarily target angiogenic pathways for HCC treatment.

MEDICINA-LITHUANIA (2023)

Article Clinical Neurology

Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease

Aron Emmi, Michele Sandre, Francesco Paolo Russo, Giulia Tombesi, Federica Garri, Marta Campagnolo, Miryam Carecchio, Roberta Biundo, Gaya Spolverato, Veronica Macchi, Edoardo Savarino, Fabio Farinati, Piero Parchi, Andrea Porzionato, Luigi Bubacco, Raffaele De Caro, Gabor G. Kovacs, Angelo Antonini

Summary: This study investigated the alterations of alpha-synuclein and glial responses in duodenum biopsies of Parkinson's disease (PD) patients. The findings provide evidence of synuclein pathology and gliosis in the duodenum of PD patients, including early cases, suggesting the important role of the gut in PD pathogenesis.

MOVEMENT DISORDERS (2023)

No Data Available